205 related articles for article (PubMed ID: 21566523)
1. Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
Vaz MA; Pachón V; Grande E; Ferreiro R; Carrato A
Anticancer Drugs; 2011 Sep; 22(8):817-21. PubMed ID: 21566523
[TBL] [Abstract][Full Text] [Related]
2. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
3. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
4. Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.
Aksu G; Ensaroglu F; Dolasik I; Temiz S; Halis H; Sener SY; Kaya A; Uygun K
J BUON; 2010; 15(4):798-9. PubMed ID: 21229650
[No Abstract] [Full Text] [Related]
5. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
6. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.
Robert G; Gabbay G; Bram R; Wallerand H; Deminière C; Cornelis F; Bernhard JC; Ravaud A; Ballanger P
Eur Urol; 2009 Jun; 55(6):1477-80. PubMed ID: 19150171
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
8. Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Medioni J; Cojocarasu O; Belcaceres JL; Halimi P; Oudard S
Ann Oncol; 2007 Jul; 18(7):1282-3. PubMed ID: 17675397
[No Abstract] [Full Text] [Related]
9. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib.
Zeng H; Li X; Yao J; Zhu Y; Liu J; Yang Y; Qiang W
Urol Int; 2009; 83(4):482-5. PubMed ID: 19996660
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy.
Lim ZD; Mahajan A; Weinberg J; Tannir NM
Am J Clin Oncol; 2013 Jun; 36(3):258-60. PubMed ID: 22441343
[TBL] [Abstract][Full Text] [Related]
11. Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma.
Chowdhury T; Prichard-Jones K; Sebire NJ; Bier N; Cherian A; Sullivan MO; O'Meara A; Anderson J
J Pediatr Hematol Oncol; 2013 Jan; 35(1):e1-3. PubMed ID: 22995920
[TBL] [Abstract][Full Text] [Related]
12. [PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
Namura K; Otake S; Sawada T; Fujikawa A; Ota J; Moriyama M
Nihon Hinyokika Gakkai Zasshi; 2015 Jan; 106(1):30-4. PubMed ID: 26399128
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
14. [Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Wang C; Takeda K; Shiba M; Takayama H; Munakata S
Hinyokika Kiyo; 2016 Aug; 62(8):407-10. PubMed ID: 27624106
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
[TBL] [Abstract][Full Text] [Related]
16. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
17. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Neill MG; Wei AC; Jewett MA
Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
[TBL] [Abstract][Full Text] [Related]
18. Dramatic effect of sunitinib with rapid but transient improvement for psoriasis in a patient with metastatic renal carcinoma.
Kato Y; Yamamoto T
J Dermatol; 2013 Dec; 40(12):1069-70. PubMed ID: 24330182
[No Abstract] [Full Text] [Related]
19. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
Teo M; Downey FP; McDermott RS
Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
[No Abstract] [Full Text] [Related]
20. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
